Hypothesis

Humanin directly interacts with the mitochondrial Hsp70 chaperone (mortalin) and shifts its activity from refolding to a holdase mode, promoting the formation of thermodynamically stable amyloid‑like aggregates that sequester misfolded proteins and reduce proteotoxicity.

Mechanistic reasoning

• Humanin is upregulated during mitochondrial stress and signals through AKT/ERK/STAT3 pathways [3].
• Mitochondrial import defects, ROS or heat trigger protein aggregation that recruits Hsp70 and Hsp60 to form dynamic deposits [2].
• The Pim1/LON protease can degrade these aggregates in yeast, indicating a regulated turnover [4].
• Yet no study shows humanin influencing chaperone activity or aggregate architecture. We propose that humanin binds mortalin’s substrate‑binding domain, allosterically lowering ATP hydrolysis rates. This converts mortalin from an active unfoldase to a stable holdase that locks nascent aggregates into ordered β‑sheet rich assemblies, analogous to the way small heat shock proteins promote amyloid formation. The resulting aggregates are less toxic because they sequester exposed hydrophobic segments and are accessible to LON‑mediated clearance when stress subsides.

Testable predictions

1. Humanin overexpression will increase co‑immunoprecipitation of mortalin with ubiquitin‑laden mitochondrial aggregates.
2. Mutating the putative humanin binding motif on mortalin (e.g., G310A) will abolish humanin‑induced aggregate formation without affecting basal mortalin ATPase activity.
3. In humanin‑null cells, stress‑induced aggregates will be smaller, more amorphous, and associated with higher levels of soluble oligomers and ROS.
4. Pharmacological stabilization of humanin‑mortalin interaction (using a peptide mimetic) will enhance aggregate formation and improve cell survival under rotenone or paraquat challenge.

Experimental approach

• Generate HEK293T lines with inducible humanin WT and a secretion‑deficient mutant (ΔMTS).
• Treat cells with antimycin A to induce mitochondrial stress.
• Perform co‑IP and cross‑linking mass spectrometry to map humanin‑mortalin interfaces.
• Measure mortalin ATPase activity in lysates ± humanin using a luciferase‑based assay.
• Filter‑trap assay and Thioflavin T staining to quantify aggregate amount and amyloid signature.
• Assess cell viability, ROS (MitoSOX), and clearance of aggregates over a 24 h recovery period.
• Repeat key experiments in mortalin G310A knock‑in CRISPR lines to test necessity.

If humanin merely acts as a signaling molecule, altering its levels will not change mortalin’s biochemical behavior or aggregate morphology. Conversely, a direct modulatory role will be supported by altered ATPase kinetics, enhanced co‑aggregation, and improved stress tolerance that disappears when the interaction surface is disrupted.

Potential pitfalls include overexpression artifacts; using physiological expression levels and endogenous tagging will mitigate this. Alternative explanations such as indirect effects via AKT signaling can be controlled by employing AKT inhibitors while preserving humanin‑mortalin binding.

This hypothesis converts the vague notion of “protective aggregation” into a concrete molecular mechanism that can be affirmed or refuted with standard biochemical and cell‑biological tools.